A Novel Autoantibody against LAG-3 in Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by immune tolerance loss, although its pathogenesis remains incompletely understood. Immune checkpoint molecules maintain peripheral tolerance, and their dysregulation contributes to autoimmunity. Autoantibodies against lymphocyte activation gene-3 (LAG-3), an immune checkpoint molecule, were identified in a subset of patients with SLE. We enrolled 130 patients with SLE, 119 patients with other autoimmune diseases, and 32 healthy controls. The sera of patients with SLE were screened for antibodies against various immune checkpoint molecules to identify clinically relevant disease-specific autoantibodies against LAG-3. Functional assays were performed to assess the effect of anti-LAG-3 autoantibodies on the interaction between LAG-3 and major histocompatibility complex (MHC) class II. Pathogenic relevance was evaluated using genetic deletion and immunization-based mouse models. Anti-LAG-3 autoantibodies were detected in 52/130 patients with SLE (40.0%) but only 4 of 119 patients with other autoimmune diseases (3.4%). These autoantibodies were associated with lupus nephritis and higher disease activity. In mice, Lag3 deletion or human LAG-3 immunization induced lupus-like autoimmunity. These findings support the clinical relevance of anti-LAG-3 autoantibodies in SLE and implicate LAG-3 checkpoint disruption in lupus-like autoimmunity.
Authors
- Hiroshi Seno (ORCID: https://orcid.org/0000-0002-8509-8128)
- Masataka Yokode (ORCID: https://orcid.org/0000-0003-0751-0188)
- Yukako Maeda (ORCID: https://orcid.org/0000-0002-9208-9860)
- Takahisa Maruno (ORCID: https://orcid.org/0000-0002-7060-4104)
- Yoshihiro Nishikawa (ORCID: https://orcid.org/0000-0002-1113-6937)
- Takafumi Yanaidani (ORCID: https://orcid.org/0000-0003-0621-3982)
- Mao Mizuta (ORCID: https://orcid.org/0009-0006-3957-5428)
- Masahiro Shiokawa (ORCID: https://orcid.org/0000-0001-6436-3888)
- Hajime Yoshifuji (ORCID: https://orcid.org/0000-0001-7082-4900)
- Yuya Muramoto (ORCID: https://orcid.org/0000-0001-5159-8397)
- Sakiko Ota (ORCID: https://orcid.org/0000-0002-4958-652X)
- Keiji Akamine (ORCID: https://orcid.org/0000-0003-2682-9020)
- Tomoaki Matsumori (ORCID: https://orcid.org/0000-0002-1220-6546)
- Ran Nakashima (ORCID: https://orcid.org/0000-0001-6247-0647)
- Takeshi Kuwada (ORCID: https://orcid.org/0000-0002-9808-4139)
- Ayako Hirata (ORCID: https://orcid.org/0000-0002-2548-8159)
- Tatsuaki Tsuruyama (ORCID: https://orcid.org/0000-0002-3118-2826)
- Kazushi Izawa (ORCID: https://orcid.org/0000-0003-1080-0936)
- Akio Morinobu (ORCID: https://orcid.org/0000-0002-4672-638X)
- Junko Takita (ORCID: https://orcid.org/0000-0002-2452-6520)
- Eitaro Hiejima (ORCID: https://orcid.org/0000-0002-6663-6656)
- Koki Chikugo (ORCID: https://orcid.org/0009-0001-7741-3984)
- Kenji Sawada (ORCID: https://orcid.org/0000-0002-9352-5249)
- Hiroyuki Yoshida (ORCID: https://orcid.org/0000-0002-2578-0782)
- Masaaki Fujita (ORCID: https://orcid.org/0000-0002-7168-6850)
- Tsutomu Chiba
- Shimpei Matsumoto
Institutions
- Kyoto University (JP)
- Kyoto Pharmaceutical University (JP)
- Kansai Electric Power Hospital (JP)
- Kobe Children's Hospital (JP)
- Kobe City Medical Center West Hospital (JP)
- Tokyo Metropolitan Children's Medical Center (JP)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-11-20
- DOI
- https://doi.org/10.64898/2026.11.14.761730
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- preprint